The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

Canadian oil producer Imperial Oil posted a rise in first-quarter profit on Friday, driven primarily by stronger margins in ...

Britain's blue-chip index notched its 15th consecutive session of gains - its longest winning streak on record - as investors ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

Viking is developing what might be a game-changing medication in the segment.

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Young US women with breast cancer are not dying from the disease as often as a decade ago, researchers reported at the ...

The Food and Drug Administration accepted Novo Nordisk’s marketing application for an oral version of its weight-loss drug Wegovy and will decide in the fourth quarter, the Danis ...

The World Health Organization plans to endorse weight-loss drugs for treating obesity in adults, marking a strategic change.

Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill ...